GET THE APP

Oral itraconazole for treatment of infantile hemangiomas: Case se | 32594
Pediatrics & Therapeutics

Pediatrics & Therapeutics
Open Access

ISSN: 2161-0665

+44 1478 350008

Oral itraconazole for treatment of infantile hemangiomas: Case series and mechanism research


5th International Conference on Pediatric Nursing & Healthcare

July 11-12, 2016 Cologne, Germany

Yuping Ran

Sichuan University, China

Posters & Accepted Abstracts: Pediat Therapeut

Abstract :

We report a case series of infantile hemangiomas (IHs) which were successfully treated with oral itraconazole (ITR), and, the possible action mechanism. The diagnosis and judgment the improvement of IHs based on clinical manifestations, noninvasive color Doppler ultrasound performance, and, dermoscopy observation. Informed consent was signature from each IHs baby's parents after enough communication. Totally 22 IHs babies (male/female=4/18) entried the treatment, they aged 2-10 (3.90�?±2.30) months, weight 4-11 (7.32�?±1.91) kg. Five cases associated with fungal infection (3 Candida spp., and 2 Malasseiza spp.). ITR capsules (12 cases) or oral solution (10 cases) with dosage of 5 mg/kg/d was applied. In the first month, the red color of the lesions became lighter and the growth of the lesions were controlled, small cracks and wrinkles appeared on the surface which divided the lesion into lobules, dermoscopic feature showed indistinct vascular network and less capillary branches. The treatment period ranged 9-168 (72.90�?±47.61) days, with the dosage of 280-9000 (3157.85�?±2213.16) mg. The clinical effective percentage was 72.73% (16/22). Compliance was judged to be very good with mild diarrhea 27.30% (6/22) that did not interruption of medication. Investigation in vitro of ITR to IHs indicated the down regulation of Hedgehog and PI3K-AKT-mTOR signaling pathways.

Biography :

Email: ranyuping@vip.sina.com

Top